Perceived risk of gastric cancer associated with long-term use of proton pump inhibitors: Bridging the gap
Abstract
Background: Long-term use of proton pump inhibitors (PPIs) has been associated with potential adverse effects, including an increased risk of gastric cancer. Despite widespread use awareness of these risks among physicians varies considerably. Understanding physicians' perceptions and prescribing behaviors is critical to improving patient safety and promoting evidence-based practices. This study aimed to assess the level of awareness and risk perception among gastroenterologists and non-gastroenterologists regarding prolonged PPI use and its association with gastric malignancy.
Aim: To assess physicians' awareness of gastric cancer risk associated with long-term PPI use and compare perceptions between specialties.
Methods: A cross-sectional observational study was conducted among 33 physicians (15 gastroenterologists and 18 non-gastroenterologists) in Israel. Participants completed a structured questionnaire evaluating knowledge, attitudes, and prescribing behaviors related to PPI use. Data were analyzed using descriptive statistics and nonparametric tests to assess differences between groups and correlation patterns. Ethical approval and informed consent were obtained.
Results: Gastroenterologists demonstrated significantly higher awareness of the potential gastric cancer risks linked to prolonged PPI use (mean awareness score: 6.9 ± 1.2) compared with non-gastroenterologists (4.1 ± 1.3, P < 0.01). Despite their awareness 80% of gastroenterologists reported frequent…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.